Surotomycin Demonstrates Low In Vitro Frequency of Resistance and Rapid Bactericidal Activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium

Surotomycin (CB-183,315) is an orally administered, minimally absorbed, selective bactericidal cyclic lipopeptide in phase 3 development for the treatment of Clostridium difficile-associated diarrhea. The aim of this study was to evaluate the emergence of resistance in C. difficile (ATCC 700057 and...

Full description

Saved in:
Bibliographic Details
Main Authors: Mascio, Carmela T. M., Chesnel, Laurent, Thorne, Grace, Silverman, Jared A.
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2014
Subjects:
Experimental Therapeutics
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4068600/
https://ncbi.nlm.nih.gov/pubmed/24798273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00124-14
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items